K. Papp, “Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies”, J of Skin, vol. 2, no. S1, p. S4, Feb. 2018.